Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.23
$0.01(0.82%)
At close: 4:00 PM EST
$1.23
$0.01(0.82%)
Day’s Range― - ―
52-Week Range$2.00 - $24.30
Previous CloseN/A
Volume1.45K
Average Volume (3M)1.09M
Market Cap
$4.50M
Enterprise Value-$5.11M
Total Cash (Recent Filing)$6.91M
Total Debt (Recent Filing)$744.84K
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 05, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-87.00
Shares Outstanding2,123,635
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-1.13
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.44
Enterprise Value/Ebitda0.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4
Revenue Forecast (FY)$35.39M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt-to-equity limits interest burden and reduces solvency risk, preserving balance-sheet flexibility. This gives the company runway to support R&D and commercial activities via equity or internal resources, lowering bankruptcy risk and enabling strategic choices over the next several months.
Scaled Revenue BaseAn expanded revenue base indicates the company has moved beyond a pre-revenue stage into commercial execution, reflecting real product sales and distribution capabilities. Sustained sales scale can support operating leverage and de-risk ongoing development programs if growth stabilizes.
Stable Gross MarginsConsistent gross margins suggest predictable cost of goods and some pricing stability for its pharmaceutical portfolio. That margin floor provides a structural opportunity: if operating expenses are controlled and revenue grows, incremental sales should flow more directly to improving operating results.
Bears Say
Persistent Negative Cash FlowSustained negative OCF and FCF require continual external funding to cover operations and capex, constraining strategic flexibility. Continued cash burn increases execution risk and could force dilutive financing or cutbacks, undermining the company’s ability to invest in commercialization and R&D long term.
Reliance On Dilutive Equity FinancingsFrequent equity-linked raises and large authorized share issuances indicate dependency on dilution to fund operations. This pattern erodes per-share economics, can deter non-dilutive capital providers, and creates governance and investor-relations challenges that persist until the company reaches sustainable positive cash flow.
Persistent Unprofitability And Negative ROEChronic losses and negative returns on shareholders' equity show the company has not converted scale into profitability. Without sustained margin expansion or materially higher revenue growth, negative ROE will continue to weigh on long-term capital efficiency and the company’s ability to create shareholder value.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $2.00 and its highest was $24.30 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $4.50M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Aug 05, 2026 which is in 27 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on May 14, 2026. The company reported -$2.5 earnings per share for the quarter, the consensus estimate of -$2.5 by $0.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -1.2.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 2,123,635 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$2.5 in its last earnings report, expectations of -$2.5. Following the earnings report the stock price went down -28.905%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---